HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Cartesian Therapeutics (NASDAQ:RNAC), maintaining a $2 price target. This reaffirmation of the Buy rating and price target suggests a positive outlook on the company's stock.
March 06, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Cartesian Therapeutics, maintaining a $2 price target.
The reiteration of a Buy rating and maintenance of a $2 price target by a reputable analyst like Mitchell Kapoor suggests a strong belief in the potential of Cartesian Therapeutics. This endorsement is likely to instill confidence in investors and could lead to a positive short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100